ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Aticaprant

Also written as “JNJ-67953964”, “14C-aticaprant” and “Aticaprant Supratherapeutic Dose”.

Its studies are mostly in Depressive Disorder, Major · Schizophrenia · Smoking · Alcoholism, led by 2 companies.

Drug pageAticaprant: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 10, 202213 company-led studies, 1 open or runningNext primary completion: Jun 21, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only121 open or runningphase 3since Jul 10, 2022Dec 15, 2015Jun 21, 2027phase 1 · NCT07615426
Eli Lilly10 open or runningphase 1since Oct 20, 2010Oct 20, 2010none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 20, 2010First study: phase 1 study in AlcoholismFirst studyNCT01232439 · 13 enrolled · United States
  2. Jun 9, 2018Named aticaprantINNProposed as its International Nonproprietary Name in WHO's List 119 · before, JNJ-67953964

TargetBeta

OPRK1 →read by rule
“Kappa opioid receptor antagonist”ChEMBL 37, by rule

Other programs on OPRK1

ProgramCompanyFurthest phaseStudies
Naltrexoneruleorexigen-therapeutics-incphase 442
NalbuphineruleTrevi Therapeuticsphase 421
nalmefeneruleH. Lundbeckphase 420
cebranopadolruleTris Pharmaphase 318
nalfurafineruletoray-industries-incphase 39
asimadolineruletioga-pharmaceuticalsphase 36
icalcaprantAbbViephase 26

Studies

The one study Eli Lilly leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01232439Alcoholism · United States1CompletedApr 201113

How it is read

Names in the registry

  • “Aticaprant”, 6 entries
  • “JNJ-67953964”, 3 entries
  • “14C-aticaprant”, 1 entry
  • “Aticaprant Supratherapeutic Dose”, 1 entry
  • “Aticaprant Therapeutic Dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.